Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Merck & Co Inc (NYSE:MRK)

63.19
Delayed Data
As of Mar 27
 +0.01 / +0.02%
Today’s Change
52.44
Today|||52-Week Range
66.80
+7.34%
Year-to-Date
Merck's Ketruda Gets Positive CHMP Opinion for Lymphoma
Mar 27 / Zacks.com - Paid Partner Content
Why Biotech Stock Gilead (GILD) Could Be a Value Trap
Mar 20 / Zacks.com - Paid Partner Content
Merck wins approval for skin cancer treatment
Mar 24 / FT.com - Paid Partner Content
Trumpcare may be healthy for Big Pharma and insurers
Mar 20 / CNNMoney.com
Pfizer's Immunotherapy for Skin Cancer Gets FDA Approval
Mar 24 / Zacks.com - Paid Partner Content
Pharma Stock Roundup: AstraZeneca's Lynparza Impresses in Study, Merck Drug Label Exp...
Mar 17 / Zacks.com - Paid Partner Content
Merck Is Dangerously Close to a Breakdown
Mar 24 / TheStreet.com - Paid Partner Content
Merck's (MRK) Keytruda Gets FDA Nod for Lymphoma Indication
Mar 15 / Zacks.com - Paid Partner Content
Merck KGaA Shares Spike After FDA Approves Skin Cancer Treatment
Mar 24 / TheStreet.com - Paid Partner Content
Celldex (CLDX) Shares Up as Q4 Loss Narrows; Sales Beat
Mar 15 / Zacks.com - Paid Partner Content
Merck Closes Acquisition of Controlling Stake in Vallee S.A
Mar 23 / Zacks.com - Paid Partner Content
Trump's pledge on drug pricing squeezes pharma stocks
Mar 07 / FT.com - Paid Partner Content
The Zacks Analyst Blog Highlights: Merck, General Electric, MasterCard and NVIDIA
Mar 21 / Zacks.com - Paid Partner Content
Trump vows to bring drug prices 'way down'
Mar 07 / CNNMoney.com
Top Research Reports for Merck, GE and Others
Mar 20 / Zacks.com - Paid Partner Content